Welcome to our dedicated page for Microbot Medical SEC filings (Ticker: MBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Microbot Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Microbot Medical's regulatory disclosures and financial reporting.
Microbot Medical Inc. reports its first revenue from the LIBERTY® Endovascular Robotic System during the fiscal quarter ended March 31, 2026, driven by a Limited Market Release. Early in the following quarter, the company began a Full Market Release.
By mid-second quarter 2026, revenue from LIBERTY had already exceeded total first quarter revenue, supported by more than doubling the number of accounts since the end of the limited release. Hospitals in six states, including Georgia, Florida, New York, Michigan, Massachusetts and North Carolina, are using the system, with Boston becoming the first city with multiple accounts.
The company highlights growing recurring orders, new accounts and a larger pipeline, as well as procedures that include what it believes is the world’s first robotic Prostatic Artery Embolization and other complex interventions. Updated occupational safety guidelines and visibility at major conferences are described as supportive of further U.S. and global commercial expansion.
Microbot Medical Inc. reported its first commercial revenue in the three months ended March 31, 2026 as it began selling the LIBERTY® Endovascular Robotic System. Revenue was $105,000, with cost of revenues of $103,000, resulting in a small gross profit while the business remains in its early launch phase.
The company recorded a net loss of $3.7 million, wider than the $2.6 million loss a year earlier, driven mainly by higher sales, general and administrative expenses as commercialization ramps, partly offset by increased financing income. Cash and cash equivalents were $3.7 million and marketable securities were $68.8 million, supporting total assets of $78.1 million and shareholders’ equity of $74.1 million.
Management notes that available cash and marketable securities are sufficient to fund operations for more than twelve months, even as the company expects continued operating losses while it scales manufacturing, sales, and ongoing development of LIBERTY® and related technologies.
Microbot Medical Inc. filed a current report describing commercial progress for its LIBERTY Endovascular Robotic System. Following the Full Market Release at the Society of Interventional Radiology annual meeting, the company reports strong interest from physicians and hospital executives and has already won multiple accounts in key sales territories.
The new accounts include two sites that previously participated in the ACCESS-PVI pivotal clinical trial, which the company highlights as validation that trial users see value in adopting LIBERTY for everyday practice. Microbot plans to further showcase LIBERTY at the Global Embolization Symposium & Technologies conference in New York in mid-May and is expanding its international commercial infrastructure, including a new Vice President of Sales for EMEA.
Microbot Medical Inc. is expanding its commercial strategy by appointing Alon Tamir as Vice President of Sales for Europe, the Middle East and Asia (EMEA) to lead regional sales and partnerships for its LIBERTY Endovascular Robotic System.
The company will keep prioritizing the U.S. market, where LIBERTY has completed a Limited Market Release and moved into Full Market Release following U.S. Food and Drug Administration clearance in September 2025. Management views EMEA as a major opportunity, noting Europe alone has an estimated 2.3 million peripheral endovascular procedures annually, and the company anticipates obtaining CE mark approval by the end of 2026.
Microbot Medical Inc. furnished an update describing how new occupational protection guidelines from the Society of Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe may support the commercial position of its LIBERTY® Endovascular Robotic System.
The guidelines focus on reducing radiation exposure and musculoskeletal strain for interventional radiology staff, including new recommendations for pregnancy protection. Microbot highlights LIBERTY’s remote, seated operation as a potential way to address radiation, ergonomics and staffing challenges, and notes that multiple U.S. and European medical societies, as well as the American Medical Association, are emphasizing stronger radiation-safety practices.
Microbot Medical Inc. filed an 8-K noting it will showcase recent commercial achievements that led to the Full Market Release (FMR) of its LIBERTY® Endovascular Robotic System at the 25th Annual Needham Virtual Healthcare Conference.
CEO Harel Gadot and senior executives will present live at 10:15 a.m. ET on April 15, 2026, discussing the company’s strategy, growth opportunities, and how LIBERTY aims to address physician radiation exposure, physical strain, and staffing issues. The presentation will be webcast via the company’s investor website, and management will also hold one-on-one meetings with healthcare-focused institutional investors.
The press release describing these plans is furnished as an exhibit and includes standard forward-looking statements language.
Microbot Medical Inc. is moving from a limited to a full U.S. market release of its LIBERTY® Endovascular Robotic System. The full launch is scheduled to coincide with the Society of Interventional Radiology Annual Scientific Meeting in Toronto, which brings together its primary U.S. target users.
LIBERTY, described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, has already been adopted by multiple healthcare systems, including hospitals such as Emory Healthcare and Tampa General Hospital. It has been used commercially in procedures like Prostate Artery Embolization, Uterine Fibroid Embolization, Genicular Artery Embolization, Y90 mapping and deliveries, and peripheral arterial interventions.
To support the full market release, the company has expanded its commercial organization, increasing its U.S. sales footprint from four to eight territories and setting a goal of 12 territories by the end of 2026. Management highlights physician feedback on LIBERTY’s precision, short learning curve, fast setup and the ability to use preferred wires and catheters, while also pointing to industry moves to strengthen protections against occupational radiation exposure as a supportive backdrop for remotely operated systems.
Microbot Medical Inc. proposes an at-the-market offering to sell up to $39,230,691 aggregate offering price of its common stock through H.C. Wainwright & Co., acting as sales agent, under an amended sales agreement.
As of December 31, 2025, Microbot reported 67,158,044 shares outstanding; the prospectus shows an as adjusted figure of 83,851,955 shares reflecting an assumed sale of 16,693,911 shares at an illustrative price of $2.35 per share (the April 8, 2026 closing price referenced). The offering permits sales on Nasdaq or by other methods permitted as an ATM; Wainwright’s commission is 3.0% of gross proceeds. The company discloses intended use of proceeds for LIBERTY® development, regulatory and commercialization activities, potential IP acquisitions, and general corporate purposes, and notes ongoing risks related to regional hostilities in Israel that could affect operations.
Microbot Medical Inc. is activating its existing at-the-market equity program with H.C. Wainwright & Co. Under this arrangement, the company may sell shares of its common stock, par value $0.01 per share, from time to time up to an aggregate offering price of $39,230,691.
Sales can occur on the Nasdaq Capital Market, through market makers, or directly to Wainwright in negotiated transactions at prevailing market prices or prices related to them. These sales will be made under a shelf registration statement on Form S-3, using a prospectus and a new prospectus supplement filed with the SEC. The company also filed a legal opinion from its counsel on the validity of the shares.
Microbot Medical Inc. director Aileen Ptucha Stockburger received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $2.37 per share, were granted on April 1, 2026, and are scheduled to expire on April 1, 2036.